The DEA's adjustments to the aggregate production quota for lisdexamfetamine are crucial for ensuring that the U.S. can meet legitimate patient demands domestically and internationally.
Blame for the ADHD medication shortages is partially placed on the DEA's quota system, which many argue has been ineffective in gauging true market demand.
Following the Adderall shortage, prescription rates increased due to greater awareness of ADHD, broader diagnostic criteria, and the expansion of telehealth services during the pandemic.
Despite production issues being resolved, a significant rise in prescription rates has continued to strain supply chains for ADHD medications.
[
Collection
]
[
|
...
]